-
Announcement of the State Food and Drug Administration on the issuance of electronic registration certificates for drugs
Time of Update: 2022-10-13
In order to implement the important decision-making and deployment of the Party Central Committee and the State Council on deepening the reform of "decentralization and management of services", optimize the business environment, further stimulate the development vitality of market players, and provide enterprises with more efficient and convenient government services, after research, it was decided to issue electronic registration certificates for drugs from November 1, 2022.
-
Enterprises in Lhasa have produced a total of 4.122 million masks and 1,350 tons of disinfectant
Time of Update: 2022-10-13
employment In the next step, in accordance with the deployment requirements of the district and municipal party committees and governments on the overall prevention and control of the epidemic and economic and social development, the Lhasa Municipal Bureau of Economy and Information Technology will resolutely implement the important instructions and requirements of "the epidemic should be prevented, the economy should be stabilized, and the development should be safe", and orderly and steadily promoted the resumption of work and production.
-
Shanghai Municipal Action Plan for Healthy Aging (2022-2025)
Time of Update: 2022-10-13
District Health Commission, Development and Reform Commission, Science and Technology Commission, Economic Committee (Commerce Commission), Education Bureau, Civil Affairs Bureau, Finance Bureau, Hum
-
Jiangsu Pharmaceutical Medical Consumables Sunshine Procurement Service Network was officially launched
Time of Update: 2022-10-13
(End) On October 9, Jiangsu Pharmaceutical Medical Consumables Sunshine Procurement Service Network was officially put into operation, which is another important measure for the Jiangsu Provincial Medical Security Bureau to continuously optimize the business environment in accordance with the requirements of "reducing links, reducing costs and opening channels" to support the innovation and development of the pharmaceutical industry.
-
In the first half of 2022, the sales of 3 anti-tumor drugs in the hospital exceeded 2 billion yuan
Time of Update: 2022-10-13
Among them, in the first half of 2022, anti-tumor drugs with higher sales in the hospital include bevacizumab injection, trastuzumab for injection, ositinib mesylate tablets, paclitaxel for injection (albumin-conjugated), goserelin acetate extended-release implant, etc.
-
The pharmaceutical circulation link has ushered in a reshuffle period, and a large number of enterprises are seeking the road to listing
Time of Update: 2022-10-13
Prior to Hengchang Pharmaceutical, the same category of enterprise Huaren Health also submitted an IPO prospectus for the ChiNext Board in May 2021, with the intention of raising 600 million yuan.
-
Operation of basic medical insurance and maternity insurance from January to August 2022
Time of Update: 2022-10-13
The income of the basic medical insurance fund for urban and rural residents is 610.
The income of the basic medical insurance fund for urban and rural residents is 610.
The income of the basic medical insurance fund for urban and rural residents is 610.
-
The consistency evaluation of generic drugs is "high prosperity continuous", and 2 varieties of one pharmaceutical company have been evaluated
Time of Update: 2022-10-13
Two varieties of Lisheng Pharmaceutical passed the consistency evaluation Recently, the application for consistency evaluation supplement of two varieties of Lisheng Pharmaceutical Folic Acid Tablets and Hydrochlorothiazide Tablets was approved by the State Drug Administration, which further demonstrated the company's research and development strength and product quality.
-
Institutions gathered to investigate pharmaceutical CXO enterprises, and the number of 4 companies was more than 100
Time of Update: 2022-10-13
Some analysts said that pharmaceutical research and development investment will continue to grow, and the penetration rate of research and development outsourcing services will continue to increase, which will help maintain the high prosperity of the CXO industry.
-
The ophthalmic treatment track has begun, and domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2022-10-13
With the increasing aging of the population and the increase in the use of electronic products, age-related eye diseases, metabolic-related eye diseases, and fundus lesions caused by high myopia are
-
Ointment broke 6 billion for the first time, and the TOP10 sold well! Only 3 varieties have been reviewed
Time of Update: 2022-10-13
As a dosage form for transdermal administration, ointment is widely used in dermatology and surgery in hospitals. Since the beginning of this year, only Hubei Heng'an Fulin Pharmaceutical's tacrolimu
-
Medical and health workers strive to protect people's health in an all-round and full-cycle manner
Time of Update: 2022-10-13
" Hu Xiaozhong, president of the health center, said that over the past few years, we have taken the general secretary's earnest instructions to heart, worked hard to build a modern health center, and strived to set an example so that the people can enjoy better basic medical services.
-
New Chinese medicine drugs have gradually entered the harvest period, and 45 new Chinese medicine drugs have been accepted
Time of Update: 2022-10-13
Recently, the Drug Evaluation Center of the State Drug Administration issued a notice on the public solicitation of opinions on the "Technical Guidelines for the Preparation and Research of Drugs for Clinical Trial of Chinese Medicines for New Drugs (Draft for Comment)".
-
The development direction of the pharmaceutical equipment industry is gradually clear, and the future transformation and upgrading will continue to accelerate
Time of Update: 2022-10-13
In addition to accelerating innovation, promoting intelligent manufacturing has also become one of the development trends of the pharmaceutical equipment industry.
In addition to accelerating innovation, promoting intelligent manufacturing has also become one of the development trends of the pharmaceutical equipment industry.
-
Under the acceleration of chemical drug innovation, the industry will rapidly differentiate
Time of Update: 2022-10-13
The chemical preparation industry refers to the manufacture of chemical preparations directly used for the prevention and treatment and diagnosis of human diseases, and it has always occupied an impo
-
Shanghai chronic disease health management new exploration: "medical and prevention integration" precision, digitalization, standardization
Time of Update: 2022-10-13
The reporter learned on the same day that in order to reduce the patient's waiting time and contact risk, Shanghai continues to explore a new model of integration of new technologies and chronic disease prevention and treatment, and artificial intelligence voice technology has been applied in the follow-up information collection and management scenarios of patients with chronic diseases.
-
Opinions on reforming and improving the management of the review and approval of radiopharmaceuticals
Time of Update: 2022-10-13
In order to encourage the declaration of research and development of radioactive drugs, the State Drug Administration has organized and drafted the Opinions on Reforming and Improving the Administrat
-
Sanshui, Foshan, Guangdong Province, has created a new growth pole for biomedicine in the Greater Bay Area
Time of Update: 2022-10-13
Guangdong Medical Valley Yundonghai Life Science Park, located in Yundonghai Street, Sanshui District, Foshan City, is under construction Courtesy of the Publicity Department of the Sanshui District P
-
The enterprise chapter of the major pharmaceutical events in September: related to business spin-offs, mergers and acquisitions, etc
Time of Update: 2022-10-13
【Buy technology】 On September 2, Yunnan Baiyao announced that the company signed the "Technology Transfer and Cooperative Development Agreement" with Peking University Hospital and Beishi Research Institute, and intends to obtain 20 million yuan of prostate-specific membrane antigen (PSMA) targeted nuclear drugs related patents developed by the latter, and the company will conduct research and development, production and commercialization activities on the cooperative targets around the world.
-
Zixin Pharmaceutical has lost money for three consecutive years, what is the reason?
Time of Update: 2022-10-13
Sichuan root, the early production area was affected by drought weather, the attention of merchants increased, and the market rose; Recently, the market situation has stabilized, the overall source of goods is not moving fast, the market price of Sichuan Qi unified goods is about 38 yuan, and the source of goods has entered the actual digestion stage.
